| Literature DB >> 30453642 |
Qing Min1, Jiaoyan Liu2, Jing Li3, Ying Wan4, Jiliang Wu5.
Abstract
Chitosan(CH)-polylactide(PLA) copolymers containing varied PLA percentages were synthesized using a group-protection method and one of them with solubility in water-based solvents was used to prepare CH-PLA/hyaluronic acid (HA) complex microspheres for the delivery of transforming growth factor-β1 (TGF-β1). An emulsification processing method was developed for producing TGF-β1-loaded CH-PLA/HA microspheres using sodium tripolyphosphate (TPP) as ionic crosslinker and the size of the microspheres was devised to the micron level in order to achieve high encapsulating efficiency. The encapsulating efficiency, swelling property and release administration of the microspheres could be synergistically regulated by PLA component, the applied TPP dose and the incorporated HA amount. In comparison to CH/HA microspheres, the CH-PLA/HA microspheres had greatly reduced TGF-β1 release rates and were able to administrate the TGF-β1 release at controlled rates over a significant longer period of time. The released TGF-β1 was detected to be bioactive when compared to the free TGF-β1. These results suggest that the presently developed CH-PLA/HA complex microspheres have promising potential in delivering TGF-β1 for cartilage repair applications where the applied TGF-β1 amount in the early stage needs to be low whilst the sustained TGF-β1 release at an appropriate dose in the later stage has to be maintained.Entities:
Keywords: chitosan; delivery of bioactive molecules; hyaluronic acid; microspheres; polylactide; transforming growth factor-β1
Year: 2018 PMID: 30453642 PMCID: PMC6321178 DOI: 10.3390/pharmaceutics10040239
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.321
Figure 1Schematic illustration (A) for synthesis of CH-PLA; FTIR spectra (B) of CH and CH-PLA; and 1H NMR spectra of CH (C) and CH-PLA (D) (PLA content in CH-PLA: 40.7 wt %).
Parameters of CH-PLA copolymers (n = 3).
| Copolymer Name | Feed Ratio of LA to PHCH (Molar Ratio) (a) | PLA percentage in CH-PLA (wt %) (b) | Solubility (c) | |
|---|---|---|---|---|
| DMSO | Acetic Acid (1.0%) | |||
| CH-PLA(1) | 2/1 | 23.6 (±1.51) | − | + |
| CH-PLA(2) | 4/1 | 38.7 (±1.46) | ± | + |
| CH-PLA(3) | 6/1 | 46.1 (±1.64) | ±± | ±± |
| CH-PLA(4) | 8/1 | 52.4 (±1.71) | ±± | ±± |
(a) Ratio of LA to glucosamine units in PHCH (phthaloyl-chitosan); (b) Contents of C, H and N in the CH-PCLs were measured using an elemental analyzer and the PLA content in CH-PLAs was estimated using the C/N ratio; (c) “−”, “±”, “±±” and “+” denote that CH-PLAs are insoluble, swelled, partially soluble or highly swelled and soluble, respectively, and DMSO refers to dimethyl sulfoxide.
Parameters of TGF-β1-loaded microspheres (n = 4) (†).
| Microsphere Name | Feed Ratio of HA to CH-PLA (mg/mg) | Feed Ratio of TPP to Matrix (mg/mg) | Average Size (µm) | ||
|---|---|---|---|---|---|
| CH-I | − | 2/1 | 3.73 (±0.41) | 29.6 (±3.4) | 69.7 (±5.1) |
| CH/HA-I(1) | 0.15/1.0 | 2/1 | 3.72 (±0.35) | 35.5 (±2.7) | 61.5 (±4.6) |
| CH/HA-I(2) | 0.3/1.0 | 2/1 | 3.74 (±0.32) | 40.7 (±2.9) | 59.1 (±3.9) |
| CH-PLA/HA-I(1) | 0.15/1.0 | 2/1 | 3.86 (±0.29) | 55.2 (±2.8) | 46.4 (±3.5) |
| CH-PLA/HA-I(2) | 0.3/1.0 | 2/1 | 4.08 (±0.25) | 61.4 (±2.5) | 44.6 (±3.1) |
| CH-II | − | 4/1 | 3.16 (±0.27) | 37.1 (±3.3) | 61.2 (±4.8) |
| CH/HA-II(a) | 0.15/1.0 | 4/1 | 3.46 (±0.31) | 46.8 (±3.1) | 53.4 (±4.3) |
| CH/HA-II(b) | 0.3/1.0 | 4/1 | 3.63 (±0.28) | 51.6 (±3.6) | 48.5 (±3.6) |
| CH-PLA/HA-II(a) | 0.15/1.0 | 4/1 | 3.83 (±0.24) | 75.3 (±3.2) | 32.3 (±3.4) |
| CH-PLA/HA-II(b) | 0.3/1.0 | 4/1 | 4.16 (±0.28) | 81.9 (±3.8) | 30.2 (±3.2) |
(†) CH-PLA with a PLA percentage of 38.7 wt % (see Table 1) was used for preparing all kinds of microspheres; ( Different sample sets: set-one ( and set-two (.
Figure 2Representative scanning electron microscopy (SEM) micrographs for (A) CH-I; (B) CH/HA-II(b) and (C) CH-PLA/HA-II(b) microspheres (arrows denote the cracked clumps and irregularly shaped beads).
Figure 3Variations in size-distribution of microspheres in set-one (A) and in set-two (B) (see Table 2 for their compositions).
Figure 4Release profiles of TGF-β1 from microspheres in set-one (A) and set-two (B) (n = 3).
Figure 5Percent mink lung cell growth inhibition (A, free TGF-β1 without storing treatment; and B, free TGF-β1 stored in DMEM (dulbecco’s modified eagle medium) at 37 °C for different time intervals changing from 10 to 21 days) of TGF-β1 released from different microspheres during varied periods (n = 3; N.S. no significance; * p < 0.05).